QGEN
Qiagen N.V.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QGEN
this stock
Qiagen N.V.
|
$8.27B | -10.8% | +5.7% | — | 3.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$194.52B | -9.6% | +0.4% | 28.8 | 1.2% |
|
DHR
Danaher Corp /De/
|
$140.09B | -13.4% | +8.5% | 38.2 | 1.6% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.00B | -17.5% | +10.4% | 41.0 | 2.7% |
|
NTRA
Natera, Inc.
|
$40.00B | +21.9% | -2.8% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QGEN | +3.0% | +10.0% | -17.2% | +2.6% | -10.8% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +1.6% | +11.3% | -25.3% | +2.8% | -20.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.